CORDIS - EU research results
CORDIS

A multifaceted cancer immunotherapy based on an immune checkpoint-modulating chimeric oncolytic virus vector in combination with a dendritic cell vaccine

Publications

Virotherapy in Germany—Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies

Author(s): Dirk M. Nettelbeck, Mathias F. Leber, Jennifer Altomonte, Assia Angelova, Julia Beil, Susanne Berchtold, Maike Delic, Jürgen Eberle, Anja Ehrhardt, Christine E. Engeland, Henry Fechner, Karsten Geletneky, Katrin Goepfert, Per Sonne Holm, Stefan Kochanek, Florian Kreppel, Lea Krutzke, Florian Kühnel, Karl Sebastian Lang, Antonio Marchini, Markus Moehler, Michael D. Mühlebach, Ulrike Naumann, Rom
Published in: Viruses, Issue 13/8, 2021, Page(s) 1420, ISSN 1999-4915
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/v13081420

Adoptive T Cell Therapy Is Complemented by Oncolytic Virotherapy with Fusogenic VSV-NDV in Combination Treatment of Murine Melanoma

Author(s): Teresa Krabbe, Janina Marek, Tanja Groll, Katja Steiger, Roland M. Schmid, Angela M. Krackhardt, Jennifer Altomonte
Published in: Cancers, Issue 13/5, 2021, Page(s) 1044, ISSN 2072-6694
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/cancers13051044

Intellectual Property Rights

AN IMMUNE CHECKPOINT-MODULATING VSV-NDV HYBRID VIRUS FOR ONCOLYTIC VIRUS IMMONOTHERAPY OF CANCER

Application/Publication number: 20 205209
Date: 2020-11-02

Searching for OpenAIRE data...

There was an error trying to search data from OpenAIRE

No results available